{"transactions":[{"id":1663777,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-01T23:00:16.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":false,"shares":9275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."}],"balance_after":27825,"derivative":{"underlying":"Common Stock, par value $0.0001","underlying_shares":9275},"source":{"system":"sec-edgar","filing":"0001104659-24-009538","document":"tm244961-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465924009538/tm244961-1_4seq1.xml","form_type":"4"}},{"id":1663776,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2024-02-01T23:00:16.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":4621,"price":2.69,"value":12430.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan (\"ESPP\"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023."}],"balance_after":45012,"source":{"system":"sec-edgar","filing":"0001104659-24-009538","document":"tm244961-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465924009538/tm244961-1_4seq1.xml","form_type":"4"}},{"id":1663775,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2024-02-01T23:00:16.000Z","date":"2024-01-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":2175,"price":9.8,"value":21315.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs."}],"balance_after":40391,"source":{"system":"sec-edgar","filing":"0001104659-24-009538","document":"tm244961-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465924009538/tm244961-1_4seq1.xml","form_type":"4"}},{"id":1663774,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2024-02-01T23:00:16.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":true,"shares":9275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested."}],"balance_after":42566,"source":{"system":"sec-edgar","filing":"0001104659-24-009538","document":"tm244961-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465924009538/tm244961-1_4seq1.xml","form_type":"4"}},{"id":1668090,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-29T23:30:13.000Z","date":"2024-01-25","kind":"grant","planned":false,"acquired":true,"shares":58400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."}],"balance_after":58400,"derivative":{"underlying":"Common Stock, par value $0.0001","underlying_shares":58400},"source":{"system":"sec-edgar","filing":"0001104659-24-007859","document":"tm244341-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465924007859/tm244341-1_4seq1.xml","form_type":"4"}},{"id":1668089,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (option to buy)","published_at":"2024-01-29T23:30:13.000Z","date":"2024-01-25","kind":"grant","planned":false,"acquired":true,"shares":163200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the shares underlying the option become vested and exercisable on January 25, 2025 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 25, 2025, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":163200,"derivative":{"exercise_price":9.28,"expiration_date":"2034-01-25","underlying":"Common Stock, par value $0.0001","underlying_shares":163200},"source":{"system":"sec-edgar","filing":"0001104659-24-007859","document":"tm244341-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465924007859/tm244341-1_4seq1.xml","form_type":"4"}},{"id":1696354,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-02T23:00:20.000Z","date":"2023-12-29","kind":"exercise","planned":false,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on December 31, 2022, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on December 31, 2022, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."}],"balance_after":25000,"derivative":{"underlying":"Common Stock, par value $0.0001","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001104659-24-000424","document":"tm241507-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465924000424/tm241507-1_4seq1.xml","form_type":"4"}},{"id":1696353,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2024-01-02T23:00:20.000Z","date":"2023-12-29","kind":"tax_withholding","planned":false,"acquired":false,"shares":3044,"price":11.25,"value":34245.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs."}],"balance_after":33291,"source":{"system":"sec-edgar","filing":"0001104659-24-000424","document":"tm241507-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465924000424/tm241507-1_4seq1.xml","form_type":"4"}},{"id":1696352,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2024-01-02T23:00:20.000Z","date":"2023-12-29","kind":"exercise","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested."}],"balance_after":36335,"source":{"system":"sec-edgar","filing":"0001104659-24-000424","document":"tm241507-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465924000424/tm241507-1_4seq1.xml","form_type":"4"}},{"id":1817751,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2023-08-02T21:51:26.000Z","date":"2023-07-31","kind":"grant","planned":false,"acquired":true,"shares":1825,"price":2.81,"value":5128.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan (\"ESPP\"). It pertains to the ESPP purchase period from February 1, 2023 through July 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2023."}],"balance_after":23835,"source":{"system":"sec-edgar","filing":"0001104659-23-086907","document":"tm2322669-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465923086907/tm2322669-4_4seq1.xml","form_type":"4"}},{"id":1939049,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2023-03-25T00:54:49.000Z","date":"2023-03-24","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":4.314,"value":43140.0,"ownership":{"direct":true},"balance_after":22010,"source":{"system":"sec-edgar","filing":"0001104659-23-036758","document":"tm2310588d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465923036758/tm2310588d1_4seq1.xml","form_type":"4"}},{"id":2035663,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2023-02-02T22:09:00.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":1172,"price":10.2085,"value":11964.362,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan (\"ESPP\"). It pertains to the ESPP purchase period from August 1, 2022 through January 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2022."}],"balance_after":12010,"source":{"system":"sec-edgar","filing":"0001104659-23-009972","document":"tm235311-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465923009972/tm235311-1_4seq1.xml","form_type":"4"}},{"id":2038400,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-01T22:31:05.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":37100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."}],"balance_after":37100,"derivative":{"underlying":"Common Stock, par value $0.0001","underlying_shares":37100},"source":{"system":"sec-edgar","filing":"0001104659-23-009353","document":"tm235142-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465923009353/tm235142-2_4seq1.xml","form_type":"4"}},{"id":2038399,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (option to buy)","published_at":"2023-02-01T22:31:05.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the shares underlying the option become vested and exercisable on January 30, 2024 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 30, 2024, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":105000,"derivative":{"exercise_price":12.88,"expiration_date":"2033-01-30","underlying":"Common Stock, par value $0.0001","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001104659-23-009353","document":"tm235142-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465923009353/tm235142-2_4seq1.xml","form_type":"4"}},{"id":2072454,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-01-03T22:59:54.000Z","date":"2022-12-31","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on December 31, 2022, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on December 31, 2022, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."}],"balance_after":37500,"derivative":{"underlying":"Common Stock, par value $0.0001","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001104659-23-000469","document":"tm231429-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465923000469/tm231429-3_4seq1.xml","form_type":"4"}},{"id":2072453,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2023-01-03T22:59:54.000Z","date":"2022-12-31","kind":"tax_withholding","acquired":false,"shares":3028,"price":16.45,"value":49810.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs."}],"balance_after":10838,"source":{"system":"sec-edgar","filing":"0001104659-23-000469","document":"tm231429-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465923000469/tm231429-3_4seq1.xml","form_type":"4"}},{"id":2072452,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2023-01-03T22:59:54.000Z","date":"2022-12-31","kind":"exercise","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested."}],"balance_after":13866,"source":{"system":"sec-edgar","filing":"0001104659-23-000469","document":"tm231429-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465923000469/tm231429-3_4seq1.xml","form_type":"4"}},{"id":2195533,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2022-08-03T20:05:43.000Z","date":"2022-07-31","kind":"grant","acquired":true,"shares":1366,"price":6.86,"value":9370.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan (\"ESPP\"). It pertains to the ESPP purchase period from February 1, 2022 through July 31, 2022."}],"balance_after":1366,"source":{"system":"sec-edgar","filing":"0001104659-22-085617","document":"tm2222488-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465922085617/tm2222488-1_4seq1.xml","form_type":"4"}},{"id":2448468,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-01-04T11:11:23.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on December 31, 2022, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on December 31, 2022, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."}],"balance_after":50000,"derivative":{"underlying":"Common Stock, par value $0.0001","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-22-000629","document":"tm2136680-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465922000629/tm2136680-3_4seq1.xml","form_type":"4"}},{"id":2448467,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (option to buy)","published_at":"2022-01-04T11:11:23.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on December 31, 2022, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date."}],"balance_after":150000,"derivative":{"exercise_price":9.16,"expiration_date":"2031-12-31","underlying":"Common Stock, par value $0.0001","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001104659-22-000629","document":"tm2136680-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465922000629/tm2136680-3_4seq1.xml","form_type":"4"}},{"id":2757087,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2021-04-05T23:15:11.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\").  Each RSU represents a contingent right to receive one share of AYTU common stock.  The RSUs vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 1, 2022, and 1/12 on the first day of each quarter thereafter, such that the RSUs will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units (\"RSUs\").  Each RSU represents a contingent right to receive one share of AYTU common stock.  The RSUs vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 1, 2022, and 1/12 on the first day of each quarter thereafter, such that the RSUs will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of restricted stock units (\"RSUs\").  Each RSU represents a contingent right to receive one share of AYTU common stock.  The RSUs vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 1, 2022, and 1/12 on the first day of each quarter thereafter, such that the RSUs will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."}],"balance_after":68734,"source":{"system":"sec-edgar","filing":"0001567619-21-007654","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761921007654/doc1.xml","form_type":"4"}},{"id":2777529,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T17:04:28.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":1.49,"underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001104659-21-039174","document":"tm219870-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039174/tm219870-4_4seq1.xml","form_type":"4"}},{"id":2777528,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T17:04:28.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":230276,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":2.31,"underlying":"Common Stock","underlying_shares":230276},"source":{"system":"sec-edgar","filing":"0001104659-21-039174","document":"tm219870-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039174/tm219870-4_4seq1.xml","form_type":"4"}},{"id":2777527,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T17:04:28.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":8.3,"underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001104659-21-039174","document":"tm219870-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039174/tm219870-4_4seq1.xml","form_type":"4"}},{"id":2777526,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T17:04:28.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":7,"underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-21-039174","document":"tm219870-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039174/tm219870-4_4seq1.xml","form_type":"4"}},{"id":2777525,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T17:04:28.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":10.74,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-21-039174","document":"tm219870-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039174/tm219870-4_4seq1.xml","form_type":"4"}},{"id":2777524,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T17:04:28.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":60230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":25.5,"underlying":"Common Stock","underlying_shares":60230},"source":{"system":"sec-edgar","filing":"0001104659-21-039174","document":"tm219870-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039174/tm219870-4_4seq1.xml","form_type":"4"}},{"id":2777523,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T17:04:28.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":9.32,"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001104659-21-039174","document":"tm219870-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039174/tm219870-4_4seq1.xml","form_type":"4"}},{"id":2777522,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T17:04:28.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":86167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":2.91,"underlying":"Common Stock","underlying_shares":86167},"source":{"system":"sec-edgar","filing":"0001104659-21-039174","document":"tm219870-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039174/tm219870-4_4seq1.xml","form_type":"4"}},{"id":2777521,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-19T17:04:28.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":126245,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. (\"Parent\"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") effective as of March 19, 2021 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the \"Exchange Ratio\") shares of Common Stock of Parent (the \"Parent Common Stock\"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement)."},{"field":"shares","element":"transactionShares","label":"F3","text":"This number includes 58,438 restricted stock units (each, an \"RSU\") held by the Reporting Person. At the Effective Time, each RSU that was outstanding prior to the Effective Time immediately and automatically ceased to represent a right to acquire shares of Company Common Stock and was assumed by Parent and converted automatically into a restricted stock unit denominated in Parent Common Stock equal to the number of Shares subject to the RSU prior to the Effective Time multiplied by the Exchange Ratio, and any cash in lieu of fractional shares of Parent Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. (\"Parent\"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") effective as of March 19, 2021 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the \"Exchange Ratio\") shares of Common Stock of Parent (the \"Parent Common Stock\"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-039174","document":"tm219870-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039174/tm219870-4_4seq1.xml","form_type":"4"}},{"id":2786106,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-16T08:49:05.000Z","date":"2021-03-02","kind":"tax_withholding","acquired":false,"shares":14825,"price":0.844,"value":12512.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of Restricted Stock Units and does not represent a sale by the Reporting Person."}],"balance_after":126245,"source":{"system":"sec-edgar","filing":"0001104659-21-036711","document":"tm219870-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921036711/tm219870-1_4seq1.xml","form_type":"4"}},{"id":2786105,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-16T08:49:05.000Z","date":"2021-03-01","kind":"tax_withholding","acquired":false,"shares":1390,"price":0.883,"value":1227.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of Restricted Stock Units and does not represent a sale by the Reporting Person."}],"balance_after":141070,"source":{"system":"sec-edgar","filing":"0001104659-21-036711","document":"tm219870-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921036711/tm219870-1_4seq1.xml","form_type":"4"}},{"id":3227328,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-04T17:22:33.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option will vest in four equal, annual installments beginning on March 2, 2021."}],"balance_after":115000,"derivative":{"exercise_price":1.49,"expiration_date":"2030-03-02","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001104659-20-029264","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465920029264/a4.xml","form_type":"4"}},{"id":3227327,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-03-04T17:22:33.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest in two equal, annual installments beginning on March 2, 2021."}],"source":{"system":"sec-edgar","filing":"0001104659-20-029264","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465920029264/a4.xml","form_type":"4"}},{"id":3618884,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-04T16:02:11.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":230276,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will vest in four equal, annual installments beginning on March 1, 2019."}],"balance_after":230276,"derivative":{"exercise_price":2.31,"expiration_date":"2029-03-01","underlying":"Common Stock","underlying_shares":230276},"source":{"system":"sec-edgar","filing":"0001104659-19-012421","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465919012421/a4.xml","form_type":"4"}},{"id":3732129,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-12-13T16:08:14.000Z","date":"2018-12-12","kind":"purchase","acquired":true,"shares":5000,"price":2.1639,"value":10819.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.1600 to $2.1666, inclusive. The reporting person undertakes to provide Neos Therapeutics, Inc., any security holder of Neos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":42460,"source":{"system":"sec-edgar","filing":"0001104659-18-072812","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465918072812/a4.xml","form_type":"4"}},{"id":4014976,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-05T17:14:09.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option will vest in four equal, annual installments beginning on March 1, 2019."}],"balance_after":56250,"derivative":{"exercise_price":8.3,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001104659-18-014877","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465918014877/a4.xml","form_type":"4"}},{"id":4014975,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-03-05T17:14:09.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest in four equal, annual installments beginning on March 1, 2019."}],"balance_after":37460,"source":{"system":"sec-edgar","filing":"0001104659-18-014877","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465918014877/a4.xml","form_type":"4"}},{"id":4338051,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-02T21:09:53.000Z","date":"2017-05-01","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option will vest in four equal, annual installments beginning on May 1, 2018."}],"balance_after":45000,"derivative":{"exercise_price":7,"expiration_date":"2027-05-01","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-17-029073","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465917029073/a4.xml","form_type":"4"}},{"id":4338050,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-05-02T21:09:53.000Z","date":"2017-05-01","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest in four equal, annual installments beginning on May 1, 2018."}],"balance_after":18710,"source":{"system":"sec-edgar","filing":"0001104659-17-029073","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465917029073/a4.xml","form_type":"4"}}]}